{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:16:50Z","timestamp":1792729010856,"version":"4.5.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,4,2]]},"abstract":"Importance<\/jats:title>Left atrial appendage elimination may improve catheter ablation outcomes for atrial fibrillation.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the safety and effectiveness of percutaneous left atrial appendage ligation adjunctive to catheter pulmonary vein isolation for nonparoxysmal atrial fibrillation.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This multicenter, prospective, open-label, randomized clinical trial evaluated the safety and effectiveness of percutaneous left atrial appendage ligation adjunctive to planned pulmonary vein isolation for nonparoxysmal atrial fibrillation present for less than 3 years. Eligible patients were randomized in a 2:1 ratio to undergo left atrial appendage ligation and pulmonary vein isolation or pulmonary vein isolation alone. Use of a 2:1 randomization ratio was intended to provide more device experience and safety data. Patients were enrolled from October 2015 to December 2019 at 53 US sites, with the final follow-up visit on April 21, 2021.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Left atrial appendage ligation plus pulmonary vein isolation compared with pulmonary vein isolation alone.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>A bayesian adaptive analysis was used for primary end points. Primary effectiveness was freedom from documented atrial arrythmias of greater than 30 seconds duration 12 months after undergoing pulmonary vein isolation. Rhythm was assessed by Holter monitoring at 6 and 12 months after pulmonary vein isolation, symptomatic event monitoring, or any electrocardiographic tracing obtained through 12 months after pulmonary vein isolation. Primary safety was a composite of predefined serious adverse events compared with a prespecified 10% performance goal 30 days after the procedure. Left atrial appendage closure was evaluated through 12 months after pulmonary vein isolation.<\/jats:p><\/jats:sec>Results<\/jats:title>Overall, 404 patients were randomized to undergo left atrial appendage ligation plus pulmonary vein isolation and 206 were randomized to undergo pulmonary vein isolation alone. Primary effectiveness was 64.3% with left atrial appendage ligation and pulmonary vein isolation and 59.9% with pulmonary vein isolation only (difference, 4.3% [bayesian 95% credible interval, \u22124.2% to 13.2%]; posterior superiority probability, 0.835), which did not meet the statistical criterion to establish superiority (0.977). Primary safety was met, with a 30-day serious adverse event rate of 3.4% (bayesian 95% credible interval, 2.0% to 5.0%; posterior probability, 1.0) which was less than the prespecified threshold of 10%. At 12 months after pulmonary vein isolation, complete left atrial appendage closure (0 mm residual communication) was observed in 84% of patients and less than or equal to 5 mm residual communication was observed in 99% of patients.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Percutaneous left atrial appendage ligation adjunctive to pulmonary vein isolation did not meet prespecified efficacy criteria for freedom from atrial arrhythmias at 12 months compared with pulmonary vein isolation alone for patients with nonparoxysmal atrial fibrillation, but met prespecified safety criteria and demonstrated high rates of closure at 12 months.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT02513797<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jama.2024.3026","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T15:19:53Z","timestamp":1712071193000},"page":"1099","source":"Crossref","is-referenced-by-count":35,"title":["Pulmonary Vein Isolation With or Without Left Atrial Appendage Ligation in Atrial Fibrillation"],"prefix":"10.1001","volume":"331","author":[{"given":"Dhanunjaya R.","family":"Lakkireddy","sequence":"first","affiliation":[{"name":"Kansas City Heart Rhythm Institute, Overland Park"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Wilber","sequence":"additional","affiliation":[{"name":"Loyola University Chicago Stritch School of Medicine, Maywood, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneet","family":"Mittal","sequence":"additional","affiliation":[{"name":"Valley Health System, Ridgewood, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tschopp","sequence":"additional","affiliation":[{"name":"Texas Cardiac Arrhythmia Research, Austin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Ellis","sequence":"additional","affiliation":[{"name":"Vanderbilt University Heart-EP, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdi","family":"Rasekh","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Hounshell","sequence":"additional","affiliation":[{"name":"MercyOne Iowa Heart Center, West Des Moines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudy","family":"Evonich","sequence":"additional","affiliation":[{"name":"UP Health System-Marquette, Marquette, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal","family":"Chandhok","sequence":"additional","affiliation":[{"name":"Bryn Mawr Medical Specialists Association, Bryn Mawr, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Berger","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Horton","sequence":"additional","affiliation":[{"name":"Texas Cardiac Arrhythmia Research, Austin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Hoskins","sequence":"additional","affiliation":[{"name":"New Mexico Heart Institute, Albuquerque"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Calkins","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Yakubov","sequence":"additional","affiliation":[{"name":"OhioHealth Heart and Vascular, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Simons","sequence":"additional","affiliation":[{"name":"AtriCure, Inc, Mason, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin R.","family":"Saville","sequence":"additional","affiliation":[{"name":"Berry Consultants, LLC, Austin, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall J.","family":"Lee","sequence":"additional","affiliation":[{"name":"AtriCure, Inc, Mason, Ohio"},{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"aMAZE Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"joi240029r1","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.ijcard.2012.12.093","article-title":"Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century.","volume":"167","author":"Ball","year":"2013","journal-title":"Int J Cardiol"},{"issue":"1","key":"joi240029r2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"issue":"FI_3","key":"joi240029r3","doi-asserted-by":"publisher","first-page":"f366","DOI":"10.1093\/europace\/eux297","article-title":"Outcomes of persistent and long-standing persistent atrial fibrillation ablation: a systematic review and meta-analysis.","volume":"20","author":"Clarnette","year":"2018","journal-title":"Europace"},{"issue":"19","key":"joi240029r4","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1408288","article-title":"Approaches to catheter ablation for persistent atrial fibrillation.","volume":"372","author":"Verma","year":"2015","journal-title":"N Engl J Med"},{"key":"joi240029r5","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3389\/fphys.2018.01458","article-title":"Atrial fibrillation mechanisms and implications for catheter ablation.","volume":"9","author":"Cheniti","year":"2018","journal-title":"Front Physiol"},{"issue":"4","key":"joi240029r6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1161\/CIRCEP.113.001084","article-title":"Anatomic analysis of the left atrial appendage after closure with the LARIAT device.","volume":"7","author":"Bartus","year":"2014","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"1","key":"joi240029r7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10840-015-9993-4","article-title":"Ischemic necrosis of the left atrial appendage at autopsy 4 weeks following epicardial suture ligation via a sub-xiphoid approach (LARIAT).","volume":"43","author":"Ellis","year":"2015","journal-title":"J Interv Card Electrophysiol"},{"issue":"3","key":"joi240029r8","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1161\/CIRCINTERVENTIONS.109.914978","article-title":"Catheter-based left atrial appendage (LAA) ligation for the prevention of embolic events arising from the LAA: initial experience in a canine model.","volume":"3","author":"Lee","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"issue":"18","key":"joi240029r9","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/j.jacc.2016.07.770","article-title":"Left atrial appendage isolation in patients with longstanding persistent AF undergoing catheter ablation: BELIEF trial.","volume":"68","author":"Di Biase","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"joi240029r10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jacep.2015.04.006","article-title":"Left Atrial Appendage Ligation and Ablation for Persistent Atrial Fibrillation: The LAALA-AF Registry.","volume":"1","author":"Lakkireddy","year":"2015","journal-title":"JACC Clin Electrophysiol"},{"issue":"6","key":"joi240029r11","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.ahj.2015.09.019","article-title":"Percutaneous alternative to the Maze procedure for the treatment of persistent or long-standing persistent atrial fibrillation (aMAZE trial): rationale and design.","volume":"170","author":"Lee","year":"2015","journal-title":"Am Heart J"},{"issue":"4","key":"joi240029r12","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/europace\/eus027","article-title":"2012 HRS\/EHRA\/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design.","volume":"14","author":"Calkins","year":"2012","journal-title":"Europace"},{"issue":"2","key":"joi240029r13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jacc.2012.06.046","article-title":"Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience.","volume":"62","author":"Bartus","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"joi240029r14","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1016\/j.hrthm.2017.05.012","article-title":"2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.","volume":"14","author":"Calkins","year":"2017","journal-title":"Heart Rhythm"},{"issue":"3","key":"joi240029r15","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/10543406.2014.888569","article-title":"Not too big, not too small: a goldilocks approach to sample size selection.","volume":"24","author":"Broglio","year":"2014","journal-title":"J Biopharm Stat"},{"issue":"4","key":"joi240029r16","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/1740774514531352","article-title":"The utility of Bayesian predictive probabilities for interim monitoring of clinical trials.","volume":"11","author":"Saville","year":"2014","journal-title":"Clin Trials"},{"issue":"5","key":"joi240029r17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.hroo.2023.03.001","article-title":"A randomized controlled trial of pulsed field ablation versus standard-of-care ablation for paroxysmal atrial fibrillation: the ADVENT trial rationale and design.","volume":"4","author":"Reddy","year":"2023","journal-title":"Heart Rhythm O2"},{"issue":"19","key":"joi240029r18","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1161\/CIRCULATIONAHA.121.057063","article-title":"Amplatzer amulet left atrial appendage occluder versus watchman device for stroke prophylaxis (Amulet IDE): a randomized, controlled trial.","volume":"144","author":"Lakkireddy","year":"2021","journal-title":"Circulation"},{"issue":"9689","key":"joi240029r19","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"joi240029r20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.","volume":"64","author":"Holmes","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"joi240029r21","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.hrthm.2014.01.019","article-title":"The effects of LAA ligation on LAA electrical activity.","volume":"11","author":"Han","year":"2014","journal-title":"Heart Rhythm"},{"issue":"2","key":"joi240029r22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1161\/CIRCULATIONAHA.109.928903","article-title":"Left atrial appendage: an underrecognized trigger site of atrial fibrillation.","volume":"122","author":"Di Biase","year":"2010","journal-title":"Circulation"},{"issue":"3","key":"joi240029r23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jacep.2020.09.002","article-title":"The left atrial appendage ostium: hotspots for localized re-entry.","volume":"7","author":"Liu","year":"2021","journal-title":"JACC Clin Electrophysiol"},{"issue":"5","key":"joi240029r24","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1161\/CIRCEP.111.962217","article-title":"Epicardial ablation for ventricular tachycardia: a European multicenter study.","volume":"4","author":"Della Bella","year":"2011","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"4","key":"joi240029r25","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.hrthm.2012.12.013","article-title":"Epicardial ablation of ventricular tachycardia: an institutional experience of safety and efficacy.","volume":"10","author":"Tung","year":"2013","journal-title":"Heart Rhythm"},{"issue":"6","key":"joi240029r26","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1161\/CIRCEP.115.003202","article-title":"Epicardial radiofrequency ablation failure during ablation procedures for ventricular arrhythmias: reasons and implications for outcomes.","volume":"8","author":"Baldinger","year":"2015","journal-title":"Circ Arrhythm Electrophysiol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2816924\/jama_lakkireddy_2024_oi_240029_1711564180.17959.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T15:19:57Z","timestamp":1712071197000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2816924"}},"subtitle":["The aMAZE Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":26,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,4,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.3026","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,2]]}}}